Bharat Biotech submitted the data of Phase 3 to the Drug Controller General of India on June 19. Covaxin, developed by Bharat Biotech, is being administered in the country since January this year.
Indian vaccine manufacturer, Bharat Biotech, submitted the data of the phase 3 trial to the Drug Controller General of India on June 19.
The Subject Expert Committee will take it up for discussion on June 22.
Hyderabad-based Bharat Biotech has indigenously developed a vaccine for Covid-19, Covaxin. Together with Serum Institute manufactured Covishield, it is being administered on a large scale in the country.
Bharat Biotech has also applied to the WHO for emergency use authorization for using Covaxin in other countries.
The company had claimed an interim efficacy of 81% in March this year.
India is the largest manufacturer of vaccines in the world. The country has an immense responsibility of not only vaccinating its population but the world.
